CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care
1.5 Credits / Hematology, Oncology
View More
Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL
2.0 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia
1.5 Credits / Hematology, Oncology
View More
New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes
1.5 Credits / Hematology, Oncology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH
October 27th 2023The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
Read More
Damoctocog Alfa Pegol Demonstrates Safety and Efficacy in Hemophilia A
October 26th 2023While clinical trials offer controlled data, real-world studies like HEM-POWR bridge gaps, confirming damoctocog alfa pegol’s effectiveness and tolerance, establishing it as a valuable hemophilia A treatment option.
Read More
Evaluating WHO's Hemophilia Treatment Choices: Patient Safety, Access Challenges
October 12th 2023A commentary questions the characterization of cryoprecipitate, which is not pathogen-reduced, as an alternative modality for treating hemophilia, despite its substantial risk of transmitting blood-borne pathogens to patients.
Read More
What We’re Reading: Rising Breast Cancer Rates; Pharmacists Walkout; School Blood Drives on Hold
October 11th 2023Advances in treatments and early detection methods have led to improved survival rates; staffing shortages and rising demands take their toll; the US blood supply is under increasing strain.
Read More
The Framework for Embracing Gene Therapy in Hemophilia Treatment
September 30th 2023Although gene therapy is anticipated to bring positive changes for people with hemophilia, choosing to receive gene therapy will require empowerment, participation, and shared decision-making, investigators write.
Read More
Altuviiio sBLA for Severe Hemophilia A in Children Accepted by FDA
September 29th 2023The supplemental biologics license application (sBLA) is supported by the results of the XTEND-Kids study, demonstrating a once-weekly 50 IU/kg dose of antihemophilic factor (recombinant) provides effective bleed protection in children with hemophilia A and can be used across clinical scenarios.
Read More
Rare Risk of Acquired Hemophilia A Seen Following COVID-19 Infection, Vaccination
March 11th 2023A group of researchers detailed a case of acquired hemophilia A (AHA) following infection and again following vaccination, and provided additional insights through their systematic review of available data.
Read More
FVIII Half-life in Patients With Hemophilia Largely Determined by Clearance of VWF
March 10th 2023These new findings suggest that variability in factor VIII (FVIII) half-life in patients, though impacted by all 3 factors, is largely attributed to variability in the clearance of endogenous von Willebrand factor (VWF).
Read More
Andexanet Alfa Fully Neutralizes Anticoagulation From Thrombotic Disorder Treatment
February 22nd 2023Researchers found that the anticoagulant effects of apixaban, betrixaban, edoxaban, and rivaroxaban were partially neutralized at an andexanet alfa dose of 50 mcg/mL and were completely neutralized at 100 mcg/mL.
Read More
FVIII Inhibitory Antibody Titer Shows Implications for Response to IST Treatment for AHA
February 13th 2023Data show that patients who have factor VIII (FVIII) inhibitor titers of 20 or higher BU/mL took longer to achieve complete responses (CR) and had lower CR rates vs patients with lower titers.
Read More